Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience

CONCLUSION: The study revealed that imatinib mesylate, a well tolerated drug, has very few cases of severe ADRs in Indian patients at the chronic stable phase of CML.

Source: Indian Journal of Pharmacology - December 13, 2022 Category: Drugs & Pharmacology Authors: Trupti Rekha Swain Siddhartha Goutam Rabindra Kumar Jena Niranjan Rout Source Type: research